nach oben

American Journal of Clinical Dermatology

Erschienen in:

01.08.2002 | Current Opinion

Vitiligo

A Manifestation of Apoptosis?

verfasst von: Carol L. Huang, Dr James J. Nordlund, Raymond Boissy

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 5/2002

Einloggen, um Zugang zu erhalten

Abstract

Vitiligo is a common cutaneous disorder that has significant biological and social consequences for those affected. It is characterized by a loss of melanocytes from the epidermis, which results in the absence of melanin, i.e. depigmentation. There are numerous hypotheses about the etiology of vitiligo, but no data to definitively prove one theory over another. It is likely that there are numerous causes for the loss of these melanocytes.

One way to approach the identification of the etiology is to determine the mechanism by which the melanocytes are destroyed. The two known mechanisms for the destruction of cells are necrosis and apoptosis. One purpose of this paper is to review the extant data that might suggest which of the two mechanisms is operative against melanocytes in patients with vitiligo. The histological data, and some laboratory data, support apoptosis, rather than necrosis, as the mechanism for removal of melanocytes. Apoptosis can be induced by a variety of factors, including immune cytokines, some environmental chemicals (for example substituted hydroquinones such as monobenzone) or other molecular mechanisms. Current therapies, such as corticosteroids and ultraviolet light, do affect apoptosis in a variety of ways.

Confirmation of apoptosis as a mechanism, and identification of how apoptosis is initiated to produce vitiligo, can serve as a basis for devising medications that might stop the progression of the disorder. The problem of vitiligo would be essentially solved if there was a medication that is well tolerated in children, adults and pregnant women, and that would halt the progression of the depigmentation. The study of apoptosis, mechanisms of its induction, and the ways to block apoptosis, is one possible way to find both the causes of depigmentation and medications to prevent its progression.

Nordlund J., Ortonne J. Mechanisms that cause abnormal skin color. In: Nordlund J., Boissy R., King R., et al., editors. The pigmentary system: physiology and pathophysiology. Oxford: Oxford University Press, 1998: 489–502

Boissy R., Nordlund J. Albinism. Dermatology in eMedicine [online]. James W., Elston D., editors. eMedicine Corporation, St. Petersburg. Available from URL: http://www.emedicine.com/derm/index/shtml [Accessed 2002 May 02]

Boissy R.E., Nordlund J.J. Molecular basis of congenital hypopigmentary disorders in humans: a review. Pigment Cell Res 1997; 10 (1-2): 12–24PubMedCrossRef

Spritz R.A. Piebaldism, Waardenburg syndrome and related genetic disorders of melanocyte development: clinical aspects. In: Nordlund J.J., Boissy R., Hearing V., et al., editors. The pigmentary system: physiology and pathophysiology. New York: Oxford University Press, 1998: 997

Nordlund J., Ortonne J. Disorders of hypopigmentation and depigmentation. In: Nordlund J., Boissy R., King R., et al., editors. Pigmentary system: physiology and pathophysiology. Oxford: Oxford University Press, 1998: 503–707

Sheth P. The differential diagnosis of vitiligo vulgaris. In: Hann S.K., Nordlund J., editors. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 101–122

Tobin D., Swanson N., Pittelkow M.R., et al. Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol 2000; 191: 407–416PubMedCrossRef

Birbeck M.S., Breathnach A.S., Everall J.D. An electron microscope study of basal melanocytes and high-level clears cells (Langerhans cells) in vitiligo. J Invest Dermatol 1961; 37: 51–64

Koh H.K., Sober A.J., Nakagawa H., et al. Malignant melanoma and vitiligo-like leukoderma: an electron microscopic study. J Am Acad Dermatol 1983; 9 (5): 696–708PubMedCrossRef

10.

Le Poole I.C., van den Wijngaard R.M., Westerhof W., et al. Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol 1993; 100 (6): 816–822PubMedCrossRef

11.

Dippel E., Haas N., Grabbe J., et al. Expression of the c-kit receptor in hypomelanosis: a comparative study between piebaldism, naevus depigmentosus and vitiligo. Br J Dermatol 1995; 132 (2): 182–189PubMedCrossRef

12.

Ito K. Ultrastructural observations of dendritic cells in the repigmented area of vitiligo: electron microscopic studies on dopa oxidase in melanocytes which are present between the epidermal basal cells in the repigmented area of vitiligo. Jap J Dermatol 1975; 85 (6): 333–349

13.

Bleehen S.S. The treatment of vitiligo with topical corticosteroids: light and electronmicroscopic studies. Br J Dermatol 1976; 94 Suppl. 12: 43–50PubMedCrossRef

14.

Morohashi M., Hashimoto K., Goodman Jr T.F., et al. Ultrastructural studies of vitiligo, Vogt-Koyanagi syndrome, and incontinentia pigmenti achromians. Arch Dermatol 1977; 13 (6): 755–766CrossRef

15.

Moellmann G., Klein-Angerer S., Scollay D.A., et al. Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. J Invest Dermatol 1982; 79 (5): 321–330PubMedCrossRef

16.

Boissy R.E., Beato K.E., Nordlund J.J., et al. Dilated rough endoplasmic reticulum and premature death in melanocytes cultured from the vitiligo mouse. Am J Pathol 1991; 138 (6): 1511–1525PubMed

17.

Boissy R.E., Liu Y.Y., Medrano E.E., et al. Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. J Invest Dermatol 1991; 97 (3): 395–404PubMedCrossRef

18.

Boissy R. Histology of vitiliginous skin. In: Hann S.K., Nordlund J., editors. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 23–34

19.

Medrano E.E., Nordlund J.J. Successful culture of adult human melanocytes obtained from normal and vitiligo donors. J Invest Dermatol 1990; 95 (4): 441–445PubMed

20.

Cui J., Shen L.Y., Wang G.C., et al. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol 1991; 97 (3): 410–416PubMedCrossRef

21.

Cui J. The melanocyte reservoir and its necessity. In: Hann S.K., Nordlund J., editors. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 163–165

22.

Ortonne J.P., MacDonald D.M., Micoud A., et al. PUVA-induced repigmentation of vitiligo: a histochemical (split-DOPA) and ultrastructural study. Br J Dermatol 1979; 101 (1): 1–12PubMedCrossRef

23.

Ortonne J.P., Schmitt D., Thivolet J., et al. PUVA-induced repigmentation of vitiligo: scanning electron microscopy of hair follicles. J Invest Dermatol 1980; 74 (1): 40–42PubMedCrossRef

24.

Galadari E., Mehregan A.H., Hashimoto K., et al. Ultrastructural study of vitiligo. Int J Dermatol 1993; 32 (4): 269–271PubMed

25.

Arrunategui A., Arroyo C., Garcia L., et al. Melanocyte reservoir in vitiligo. Int J Dermatol 1994; 33 (7): 484–487PubMedCrossRef

26.

Nordlund J.J., Ortonne J.P. Vitiligo vulgaris. In: Nordlund J., Boissy R., King R., et al., editors. The pigmentary system: physiology and pathophysiology. Oxford: Oxford University Press, 1998: 513–553

27.

Halder R., Nordlund J. Surgical treatment of pigmentary disorders. In: Nordlund J., Boissy R., King R., et al., editors. The pigmentary system: physiology and pathophysiology. Oxford: Oxford University Press, 1998: 987–994

28.

Falabella R. Surgical therapies for vitiligo. In: Hann S.K., Nordlund J., editors. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 193–202

29.

Malmusi M., Ackerman A. A critical review of apoptosis in historical perspective. Am J Dermatopathol 2000; 22: 291–293PubMedCrossRef

30.

Mishima Y., Kawasaki H., Pinkus H., et al. Dendritic cell dynamics in progressive depigmentations: distinctive cytokinetics of -dendritic cells revealed by electron microscopy. Arch Dermatol Forsch 1972; 243 (2): 67–87PubMed

31.

Abdel-Naser M.B., Kruger-Krasagakes S., Krasagakis K., et al. Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo. Pigment Cell Res 1994; 7 (1): 1–8PubMedCrossRef

32.

Blois M. Phagocytosis of melanin particles by human epidermal cells in vitro. J Invest Dermatol 1968; 50: 336–337PubMed

33.

Wolff K., Konrad K. Melanin pigmentation: an in vivo model for studies of melanosome kinetics within keratinocytes. Science 1971; 174: 1034–1035PubMedCrossRef

34.

Ortonne J.P., Bose S.K. Vitiligo: where do we stand? Pigment Cell Res 1993; 6 (2): 61–72PubMedCrossRef

35.

Cummings M., Nordlund J.J. Chemical leukoderma: fact or fancy. Am J Contact Derm 1995; 6: 122–127CrossRef

36.

Gellin G.A., Possick P.A., Perone V.B., et al. Depigmentation from 4-tertiary butyl catechol: an experimental study. J Invest Dermatol 1970; 55: 190–197PubMedCrossRef

37.

Lerner A.B. On the etiology of vitiligo and gray hair. Am J Med 1971; 51 (2): 141–147PubMedCrossRef

38.

Oliver E.A., Schwartz L. Occupational leukoderma. Arch Dermatol Syph 1940; 42: 993–1014CrossRef

39.

Malten K.E., Seutter E. Occupational vitiligo due to paratertiary butylphenol and homologues. Trans St Johns Hosp Dermatol Soc 1971; 57 (1): 115–134PubMed

40.

Calnan C.D. Occupational leukoderma from alkyl phenols. Proc R Soc Med 1973; 66 (3): 258–260PubMed

41.

Bentley-Phillips R. Occupational leucoderma following misuse of a disinfectant. South Afr Med J 1974; 48 (19): 810

42.

Goldmann P.J., Thiess A.M. Occupational vitiligo caused by para-tertiary-butylphenol, a trial of vitiligo, hepatosis and struma. Hautarzt 1976; 27 (4): 155–159PubMed

43.

Rodermund O.E. Occupational vitiligo caused by paratertiary butylphenol [letter]. Arch Dermatol 1976; 112 (4): 554–555PubMedCrossRef

44.

James O., Mayes R.W., Stevenson C.J., et al. Occupational vitiligo induced by p-tertbutylphenol, a systemic disease? Lancet 1977; II (8050): 1217–1219CrossRef

45.

Ebner H., Helletzgruber M., Hofer R., et al. Vitiligo from p-tert butylphenol; a contribution to the problem of the internal manifestations of this occupational disease [in German]. Derm Beruf Umwelt 1979; 27 (4): 99–104PubMed

46.

Gellin G.A., Maibach H.I., Misiaszek M.H., et al. Detection of environmental depigmenting substances. Contact Dermatitis 1979; 5 (4): 201–213PubMedCrossRef

47.

Arievich A.M., Selisskii G.D. Occupational vitiligo. Vestn Dermatol Venerol 1980; (5): 46–49PubMed

48.

Frenk E., Loi-Zedda P. Occupational depigmentation due to a hydroquinone-containing photographic developer. Contact Dermatitis 1980; 6 (3): 238–239PubMedCrossRef

49.

Swarbrick P. Vitiligo as an occupational disease. Occup Health (Lond) 1980; 32 (9): 442–448

50.

O’Sullivan J.J., Stevenson C.J. Screening for occupational vitiligo in workers exposed to hydroquinone monomethyl ether and to paratertiary-amyl-phenol. Br J Ind Med 1981; 38 (4): 381–383PubMed

51.

Romaguera C., Grimalt F. Occupational leukoderma and contact dermatitis from paratertiary-butylphenol. Contact Dermatitis 1981; 7 (3): 159–160PubMedCrossRef

52.

Stevenson C.J. Occupational vitiligo: clinical and epidemiological aspects. Br J Dermatol 1981; 105 Suppl. 21: 51–56PubMedCrossRef

53.

Goette D.K. Raccoon-like periorbital leukoderma from contact with swim goggles. Contact Dermatitis 1984; 10 (3): 129–131PubMedCrossRef

54.

Das M., Tandon A. Occupational vitiligo. Contact Dermatitis 1988; 19: 184–185CrossRef

55.

O’Malley M.A., Mathias C.G., Priddy M., et al. Occupational vitiligo due to unsuspected presence of phenolic antioxidant byproducts in commercial bulk rubber. J Occup Med 1988; 30 (6): 512–516PubMedCrossRef

56.

Gawkrodger D.J., Cork M.J., Bleehan S.S., et al. Occupational vitiligo and contact sensitivity to para-tertiary butyl catechol. Contact Dermatitis 1991; 25 (3): 200–201PubMedCrossRef

57.

Tosti A., Gaddoni G., Piracinni B.M., et al. Occupational leukoderma due to phenolic compounds in the ceramics industry? Contact Dermatitis 1991; 25 (1): 67–68PubMedCrossRef

58.

Jimbow K., Obata H., Pathak M.A., et al. Mechanism of depigmentation by hydroquinone. J Invest Dermatol 1974; 62 (4): 436–449PubMedCrossRef

59.

Mans D., Lafleur M., Westmijze E.J., et al. Reactions of glutathione with the catechol, the ortho-quinone and semi-quinone free radical of etoposide: consequences for DNA inactivation. Biochem Pharmacol 1992; 43: 1761–1768PubMedCrossRef

60.

Halliwell B., Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr 1993; 57 Suppl. 5: 715S–724SPubMed

61.

Nakagawa Y., Tayama S., Moore G., et al. Cytotoxic effects of biphenyl and hydroxybiphenyls on isolated rat hepatocytes. Biochem Pharmacol 1993; 45: 1959–1965PubMedCrossRef

62.

Yang F., Abdel Malek Z., Boissy R.E., et al. Effects of commonly used mitogens on the cytotoxicity of 4-tertiary-butylphenol to human melanocytes. In Vitro Cell Dev Biol Anim 1999; 35: 566–570PubMedCrossRef

63.

Yang F., Sarangarajan R., Le Poole I.C., et al. The cytotoxicity and apoptosis induced by 4-tertiary butylphenol in human melanocytes are independent of tyrosinase activity. J Invest Dermatol 2000; 114: 157–164PubMedCrossRef

64.

Yang F., Bossy R. Effects of 4-tertiary butylphenol on the tyrosinase activity in human melanocytes. Pigment Cell Res 1999; 12: 237–245PubMedCrossRef

65.

Ros J., Rodrigues-Lopex J., Varon R., et al. Kinetic study of the oxidation of 4-tertbutyl phenol by tyrosinase. Eur J Biochem 1994; 222: 449–452PubMedCrossRef

66.

Jimenez M., Garcia-Carmona G. Hydrogen peroxide-dependent 4 t-butylphenol hydroxylation by tyrosinase: a new catalytic activity. Biochim Biophys Acta 1996; 1287: 33–39CrossRef

67.

Thorneby-Andersson K., Sterner O., Hansson C.L. Tyrosinase-mediated formation of a reactive quinone from the depigmenting agents, 4-tert butylphenol and 4 tert butylcatechol. Pigment Cell Res 2000; 13: 33–38PubMedCrossRef

68.

Orrechia G. Alternative therapies for vitiligo. In: Hann S.K., Nordlund J., editors. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 222–242

69.

Schallreuter K., Moore J. Pseudocatalase in the treatment of vitiligo. In: Hann S.K., Nordlund J., editors. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 182–192

70.

Okamoto H., Mizuno K., Itoh T., et al. Evaluation of apoptotic cells induced by ultraviolet light B radiation in epidermal sheets stained by the TUNEL technique. J Invest Dermatol 1999; 113: 802–807PubMedCrossRef

71.

Van Den Wijngaard R., Aten J., Scheepmaker A., et al. Expression and modulation of apoptosis regulatory molecules in human melanocytes: significance in vitiligo. Br J Dermatol 2000; 143: 573–581PubMedCrossRef

72.

Parrish J.A., Fitzpatrick T.B., Shea C., et al. Photochemotherapy of vitiligo: use of orally administered psoralens and a high-intensity long-wave ultraviolet light system. Arch Dermatol 1976; 112 (11): 1531–1534PubMedCrossRef

73.

Theodoridis A., Tsambaos D., Sivenas C. Oral trimethylpsoralen in the treatment of vitiligo. Acta Dermatol Venereol 1976; 56 (3): 253–256

74.

Gupta A.K., Anderson T.F. Psoralen photochemotherapy. J Am Acad Dermatol 1987; 17 (5 Pt 1): 703–734PubMedCrossRef

75.

Tham S.N., Gange R.W., Parrish J.A. Ultraviolet-B treatment of psoriasis in patients with concomitant vitiligo [letter]. Arch Dermatol 1987; 123 (1): 26–27PubMedCrossRef

76.

Ortel B., Tanew A., Honigsmann H. Treatment of vitiligo with khellin and ultraviolet A. J Am Acad Dermatol 1988; 18 (4 Pt 1): 693–701PubMedCrossRef

77.

Honigsmann H. Phototherapy and photochemotherapy. Sem Dermatol 1990; 9 (1): 84–90

78.

Antoniou C., Katsambas A. Guidelines for the treatment of vitiligo. Drugs 1992; 43 (4): 490–498PubMedCrossRef

79.

Karppinen L., Lassus A. Treatment of vitiligo with 5-methoxypsoralen and selective ultraviolet phototherapy (SUP). Nouv Dermatol 1992; 11: 709–714

80.

Skouge J.W., Morison W.L., Diwan R.V., et al. Autografting and PUVA: a combination therapy for vitiligo. J Dermatol Surg Oncol 1992; 18 (5): 357–360PubMed

81.

Imamura S., Tagami H. Treatment of vitiligo with oral corticosteroids. Dermatologica 1976; 153 (3): 179–185PubMedCrossRef

82.

Kumari J. Vitiligo treated with topical clobetasol propionate. Arch Dermatol 1984; 120 (5): 631–635PubMedCrossRef

83.

Goldstein E., Haberman H.F., Menon I.A., et al. Non-psoralen treatment of vitiligo; part I: cosmetics, systemic coloring agents, and corticosteroids. Int J Dermatol 1992; 31 (4): 229–236PubMedCrossRef

84.

Pasricha J.S., Khaitan B.K. Oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. Int J Dermatol 1993; 32 (10): 753–757PubMedCrossRef

85.

Leffell D. The scientific basis of skin cancer. J Am Acad Dermatol 2000; 42 (1 Pt 2): 18–22PubMedCrossRef

86.

McKay B., Chen F., Perumalswami C.R., et al. The tumor suppressor p53 can both stimulate and inhibit ultraviolet light-induced apoptosis. Mol Biol Cell 2000; 11: 2543–2551PubMed

87.

Zhai S., Yaar M., Doyle S.M., et al. Nerve growth factor rescues pigment cells from ultraviolet-induced apoptosis by upregulating BCL-2 levels. Exp Cell Res 1996; 224: 335–343PubMedCrossRef

88.

Petit-Frere C., Capulas E., Lyon D.A., et al. Apoptosis and cytokine release induced by ionizing or ultraviolet B radiation in primary and immortalized human keratinocytes. Carcinogenesis 2000; 21: 1087–1095PubMedCrossRef

89.

Hofs T. Humoral and cellular autoimmunity in genuine vitiligo studied by means of an antigen produced from melanoma cells. Folia Haematol Int Mag Klin Morphol Blutforsch 1982; 109 (2): 244–250PubMed

90.

Naughton G.K., Eisinger M., Bystryn J.C. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol 1983; 81 (6): 540–542PubMedCrossRef

91.

Betterle C., Mirakian R., Doniach D., et al. Antibodies to melanocytes in vitiligo [letter]. Lancet 1984; I (8369): 159CrossRef

92.

Naughton G.K., Lipkin G., Bystryn J.C. Expression of vitiligo antigen on a revertant line of hamster melanoma cells. J Invest Dermatol 1984; 83 (5): 317–319PubMedCrossRef

93.

Bystryn J.C., Naughton G.K. The significance of vitiligo antibodies. J Dermatol 1985; 12 (1): 1–9PubMedCrossRef

94.

Morgan M, Castells A., Ramirez A. Autoantibodies in vitiligo: clinical significance [in Spanish]. Med Cutan Ibero Lat Am 1986; 14 (2): 139–142PubMed

95.

Naughton G.K., Mahaffey M., Bystryn J.C. Antibodies to surface antigens of pigmented cells in animals with vitiligo. Proc Soc Exp Biol Med 1986; 181 (3): 423–426PubMed

96.

Naughton G.K., Reggiardo D., Bystryn J.C. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986; 15 (5 Pt 1): 978–981PubMedCrossRef

97.

Bystryn J.C., Pfeffer S. Vitiligo and antibodies to melanocytes. Prog Clin Biol Res 1988; 256: 195–206PubMed

98.

Norris D.A., Kissinger R.M., Naughton G.M., et al. Evidence for immunologic mechanisms in human vitiligo: patients sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988; 90 (6): 783–789PubMedCrossRef

99.

Bystryn J.C. Serum antibodies in vitiligo patients. Clin Dermatol 1989; 7 (2): 136–145PubMedCrossRef

100.

Cui J., Harning R., Henn M., et al. Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 1992; 98 (2): 162–165PubMedCrossRef

101.

Cui J., Arita Y., Bystryn J.C. Cytolytic antibodies to melanocytes in vitiligo. J Invest Dermatol 1993; 100 (6): 812–815PubMedCrossRef

102.

Fishman P., Azizi E., Schoenfeld Y., et al. Vitiligo autoantibodies are effective against melanoma. Cancer 1993; 72 (8): 2365–2369PubMedCrossRef

103.

Merimsky O., Shoenfeld Y., Chaitchik S., et al. Antigens and antibodies in malignant melanoma. Tumour Biol 1994; 15 (4): 188–202PubMedCrossRef

104.

Song Y.H., Connor E., Li Y., et al. The role of tyrosinase in autoimmune vitiligo. Lancet 1994; 344 (8929): 1049–1052PubMedCrossRef

105.

Cui J., Arita Y., Bystryn J.C. Characterization of vitiligo antigens. Pigment Cell Res 1995; 8 (1): 53–59PubMedCrossRef

106.

Cui J., Bystryn J.C. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells. Arch Dermatol 1995; 131 (3): 314–318PubMedCrossRef

107.

Cui J., Chen D., Misfeldt M.L., et al. Antimelanoma antibodies in swine with spontaneously regressing melanoma. Pigment Cell Res 1995; 8 (1): 60–63PubMedCrossRef

108.

Gilhar A., Zelickson B., Ulman Y., et al. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 1995; 105 (5): 683–686PubMedCrossRef

109.

Hara I., Takechi Y., Houghton A.N. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 1995; 182 (5): 1609–1614PubMedCrossRef

110.

Kemp E.H., Gawkrodger D.J., Watson P.F., et al. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Clin Exp Immunol 1997; 109 (3): 495–500PubMedCrossRef

111.

Duvic M., Rapini R., Hoots W.K., et al. Human immunodeficiency virus-associated vitiligo: expression of autoimmunity with immunodeficiency? J Am Acad Dermatol 1987; 17 (4): 656–662PubMedCrossRef

112.

Spickett G., Prentice A.G., Wallington T., et al. Alopecia totalis and vitiligo in common variable immunodeficiency. Postgrad Med J 1991; 67 (785): 291–294PubMedCrossRef

113.

Tojo N., Yoshimura N., Yoshizawa M. Vitiligo and chronic photosensitivity in human immunodeficiency virus infection. Jpn J Med 1991; 30 (3): 255–259PubMedCrossRef

114.

Tanus T., Levinson A.I., Atkins P.C. Polyautoimmune syndrome in common variable immunodeficiency. J Int Med 1993; 234 (5): 525–527CrossRef

115.

Garcia-Patos Briones V., Rodriguez Cano L., Capdevila Morell J.A. Vitiligo associated with the acquired immunodeficiency syndrome [letter]. Med Clin 1994; 103 (9): 358

116.

Cho M., Cohen P.R., Duvic M. Vitiligo and alopecia areata in patients with human immunodeficiency virus infection. South Med J 1995; 88 (4): 489–491PubMedCrossRef

Titel: Vitiligo
A Manifestation of Apoptosis?
verfasst von: Carol L. Huang
Dr James J. Nordlund
Raymond Boissy
Publikationsdatum: 01.08.2002
Verlag: Springer International Publishing
Erschienen in: American Journal of Clinical Dermatology / Ausgabe 5/2002
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI: https://doi.org/10.2165/00128071-200203050-00001

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2002

Clindamycin/Benzoyl Peroxide Gel

Human Herpesvirus 7 in Dermatology

Cutaneous Drug Reaction Case Reports

Complementary/Alternative Medicine in Dermatology

Cutaneous Tuberculosis